Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells

Urologia Internationalis

Volumn 82, Issue 2, 2009, Pages 214-221

  Wang, Yan ^a   An, Ruihua ^a   Dong, Xuesong ^a   Pan, Shangha ^a   Duan, Guowen ^b   Sun, Xueying ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Apoptosis; Arsenic trioxide; Bladder cancer; Proliferation; Protein kinase C

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ARSENIC TRIOXIDE; CASPASE 3; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOIMMUNOASSAY; UPREGULATION; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; HUMANS; OXIDES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 63449093838     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000200803     Document Type: Article

References (46)

1. Kitamura H, Tsukamoto T: Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol 2006; 11: 28-37.
2. Tsukamoto T, Kitamura H, Takahashi A, Masumori N: Treatment of invasive bladder cancer. Lessons from the past and perspective for the future. Jpn J Clin Oncol 2004; 34: 295-306.
3. Antman KH: Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001; 6(suppl 2):1-2.
4. Dai J, Weinberg SR, Waxman S, Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
5. Chen YC, Lin-shiau SY, Lin JK: Involvement of reactive oxygen species and caspase-3 activation in arsenic-induced apoptosis. J Cell Physiol 1998; 177: 324-333.
6. Park WH, Seol JG, Kim ES, et al: Arsenic trioxide- mediated growth inhibition in MC/ CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000; 60: 3065-3071.
7. Zhu XH, Shen YL, Jing YK, et al: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772-778.
8. Tong Q, Zeng F, Zheng L, Zhao J, Lu G: Apoptosis inducing effects of arsenic trioxide on human bladder cancer cell line BIU- 87. Chin Med J 2001; 114: 402-406.
9. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH: Arsenic trioxide as a novel anticancer agent against human transitional carcinoma characterizing its apoptotic pathway. Anticancer Drugs 2002; 13: 293-300.
10. Zhou J, Zeng FQ, Li C, et al: Preparation of arsenic trioxide-loaded albuminutes immuno- nanospheres and its specific killing effect on bladder cancer cell in vitro. Chin Med J 2005; 118: 50-55.
11. Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH: Cytotoxicity of arsenic trioxide to transitional carcinoma cells. Urology 2002; 60: 346-350.
12. Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD: Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol 2006; 36: 99-133.
13. Abernathy CO, Liu YP, Longfellow D, et al: Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect 1999; 107: 593-597.
14. Simeonova PP, Luster MI: Mechanisms of arsenic carcinogenicity: genetic or epigenetic mechanisms? J Environ Pathol Toxicol Oncol 2000; 19: 281-286.
15. Bode AM, Dong Z: The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 2002; 42: 5-24.
16. Nishizuka Y: The molecular heterogeneity of rotein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-665.
17. Lahn M, Sundell K, Moore S: Targeting protein kinase C-alpha in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen. Ann NY Acad Sci 2003; 1002: 263-270.
18. Sachs CW, Safa AR, Harrison SD, Fine RL: Partial inhibition of multidrug resistance by safingol is independent of modulation of Pglycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 1995; 270: 26639-26648.
19. Chaudhary PM, Roninson IB: Activation of MDR1 gene expression in human cells by protein kinase C agonists. Oncol Res 1992; 4: 281-290.
20. Denning MF, Wang Y, Tibudan S, Alkan S, Nickoloff BJ, Qin JZ: Caspase activation and disruption of mitochondrial membrane potential during UV radiation-induced apoptosis of human keratinocytes requires activation of protein kinase C. Cell Death Differ 2002; 9: 40-52.
21. Cheng AL, Chuang SE, Fine RL, et al: Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998; 55: 523-531.
22. Newton AC: Protein kinase C: seeing two domains. Curr Biol 1995; 5: 973-976.
23. Liu B, Pan S, Dong X, et al: Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 2006; 97: 675-681.
24. Akao Y, Nakagawa Y, Akiyama K: Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase-3 in vitro. FEBS Lett 1999; 455: 59-62.
25. Seol JG, Park WH, Kim ES, et al: Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 1999; 265: 400-404.
26. Zhang TC, Cao EH, Li JF, Ma W, Qin JF: Induction of apoptosis and inhibition of human gastric cancer MCG-803 cell growth by arsenic trioxide. Eur J Cancer 1999; 35: 1258-1263.
27. Uslu R, Sanli UA, Sezgin C, et al: Arsenic trioxide- mediated cytotoxicity and apoptosis in prostate and ovarian cell lines. Clin Cancer Res 2000; 6: 4957-4964.
28. Hyun PW, Hee CY, Won JC, et al: Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003; 300: 230-235.
29. Shen ZY, Zhang Y, Chen JY, et al: Intratumoral injection of arsenic to enhance anti tumor efficacy in human esophageal carcinoma cell xenografts. Oncol Rep 2004; 11: 155-159.
30. Maeda H, Hori S, Nishitoh H, et al: Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61: 5432-5440.
31. Nakagawa Y, Akao Y, Morikawa H, et al: Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002; 70: 2253-2262.
32. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y: Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2002; 291: 861-867.
33. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H: Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukemia? Br J Haematol 2001; 112: 783-786.
34. Wang ZG, Rivi R, Delva L, et al: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998; 92: 1497-1504.
35. Baumgartner M, Sturlan S, Roth E, Wessner B, Bachleitner-Hofmann T: Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 2004; 112: 707-712.
36. Shen ZX, Shi ZZ, Fang J, et al: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335.
37. El Bougrini J, Pampin M, Chelbi-Alix MK: Arsenic enhances the apoptosis induced by interferon gamma: key role of IRF-1. Cell Mol Biol 2006; 52: 9-15.
38. Chen D, Chan R, Waxman S, Jing Y: Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res 2006; 66: 11416-11423.
39. Kim HR, Kim EJ, Yang SH, et al: Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. Int J Oncol 2006; 28: 1401-1408.
40. Cheung WM, Chu PW, Kwong YL: Effects of arsenic trioxide on the cellular proliferation, apoptosis and differentiation of human neuroblastoma cells. Cancer Lett 2007; 246: 122-128.
41. Woo SY, Lee MY, Jung YJ, et al: Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol 2006; 23: 231-243.
42. Nakabo Y, Pabst MJ: Inhibition by sphingosine of leukemic cell killing by human monocytes activated with interleukin-2: a possible role of protein kinase C. Jpn J Cancer Res 1998; 89: 548-555.
43. Hamada M, Sumi T, Iwai S, Nakazawa M, Yura Y: Induction of endonuclease G-mediated apopotosis in human oral squamous cell carcinoma cells by protein kinase C inhibitor safingol. Apoptosis 2006; 11: 47-56.
44. Schwartz GK, Ward D, Saltz L, et al: A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 1997; 3: 537-543.
45. Varga A, Czifra G, Tallai B, et al: Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol 2004; 46: 462-465.
46. Langzam L, Koren R, Gal R, et al: Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Am J Clin Pathol 2001; 116: 377-385.